A six-month gluten-free diet significantly eased disability and supported a healthier body composition in women with relapsing-remitting multiple sclerosis (RRMS), a new small study found. The findings support growing evidence linking the gut-brain axis and metabolic inflammation to MS, and suggest that a gluten-free diet may be a promising dietary…
News
Octave Bioscience is entering into a collaboration with Quest Diagnostics to expand access to its multiple sclerosis disease activity (MSDA) test, which uses data from a set of blood biomarkers to measure how active a patient’s disease is in people with multiple sclerosis (MS). Although the MSDA…
People who drink coffee may have a more than 20% lower risk of developing multiple sclerosis (MS) compared with those who do not, according to a new analysis of published studies that pooled data from more than 4,500 participants from seven countries. “These results suggest that coffee consumption might…
Lynk Pharmaceuticals has received the green light from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its investigational oral therapy LNK01006, which is being developed for multiple sclerosis (MS) and other neuroinflammatory diseases. “We look forward to advancing this promising molecule into human clinical…
For most people with multiple sclerosis (MS), the use of disease-modifying therapies, or DMTs, does not affect their perceived pain, according to a survey-based study in Australia. As few as one-third of MS patients who had ever used DMTs reported a change in pain, while one-eighth of those…
Adherence to either the Mediterranean or the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets was associated with better performance in certain areas of thinking and memory among people with multiple sclerosis (MS), a U.K. study suggests. The Mediterranean diet reflects foods traditionally eaten in countries around the Mediterranean Sea.
Aquatic therapy significantly eased fatigue and improved balance in multiple sclerosis (MS) patients in a clinical trial in Greece, outperforming results from a control group who participated in a conventional physiotherapy program. “Our work suggests that incorporating [aquatic therapy] into MS care can meaningfully alleviate fatigue and balance deficits,…
People with multiple sclerosis (MS) who have higher levels of Fusobacterium nucleatum in the mouth — bacteria that can contribute to periodontitis, a serious gum infection — may be more likely to experience more severe symptoms, according to a study from Japan. This finding adds to recent preclinical evidence…
Resistance training may be the most effective type of exercise for easing fatigue in people with multiple sclerosis (MS), especially when programs last longer than eight weeks, a meta-analysis found. The study, “Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis…
Disability progression is not always permanent for people with relapsing-remitting multiple sclerosis (RRMS), even when it occurs independent of a relapse, a new study has found. Researchers report that nearly one-third of RRMS patients who experience progression independent of relapse activity (PIRA) see their disability levels ease in the…
Oligodendrocytes, the cells that build and repair myelin in the brain and spinal cord, may play a role in the inflammatory processes involved in multiple sclerosis (MS), even at the earliest stages of disease, according to a study in a mouse model. “We found that oligodendrocytes transition to disease…
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children…
Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) — may offer a clearer way to track both disease activity and disability progression in people with multiple sclerosis (MS), according to a new long-term study. Each…
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received…
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the…
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is safe and may help reduce disease activity in people with multiple sclerosis (MS). The Phase 2 study (NCT06735248) aims to enroll 180 adults, ages 18 to 55, with…
Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions, with different immune signatures, a study found. These findings help explain why treatments approved for MS generally show limited effectiveness for MOGAD, researchers said. “These findings support MOGAD as its…
Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Vumerity (diroximel fumarate) for adults with relapsing forms of multiple sclerosis (MS) and other conditions. The drug will be sold as 231 mg delayed-release capsules, produced at Zydus’s…
Mesenchymal stem cell therapy shows promise for treating multiple sclerosis (MS), with improvements seen in disability, walking ability, vision, and auditory function, according to a recent review of published studies. The approach also seems to be well tolerated by people with MS, but more research is needed on…
A new technique is letting scientists peer into the brain’s wiring with greater detail by simply using a microscope and an LED light, an accessible and cost-effective method that may be useful for studying brain damage in neurological diseases such as multiple sclerosis (MS). The method, called Computational Scattered…
Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called “unprecedented results,” two late-stage trials testing…
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier to track disease progression and guide personalized care. Researchers showed the system, OPM-MEG, reliably detects abnormalities in the brain’s electrical activity in MS patients. The portable technology is a major…
When the lights come up at the MS Focus on Fashion gala, the runway will be more than a showcase for beautiful designs. The Nov. 14 event in Fort Lauderdale, Florida, will be a celebration of confidence and connection for people living with multiple sclerosis (MS), according to…
Scientists at Case Western Reserve University (CWRU) in Ohio will use a new $2.5 million donation from the Thomas F. Peterson Jr. Charitable Trust to develop therapeutic strategies for multiple sclerosis (MS) and other neurological diseases. The commitment will support Paul Tesar, PhD, a CWRU professor and director of the…
Sativex (nabiximols) — a cannabis-based oral spray used to ease spasticity in certain people with multiple sclerosis (MS) — has been acquired by CNX Therapeutics, which will now market the therapy in Europe and other international regions. The therapy, previously developed by Jazz Pharmaceuticals, is approved as…
Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve fibers that is damaged in multiple sclerosis (MS), in large areas of the brain, according to a study. The tool may help assess the extent of myelin damage in…
A robotic exoskeleton dubbed Atalante X, which allows people with severe mobility issues to stand upright for rehabilitation exercises, is now cleared by the U.S. Food and Drug Administration (FDA) for use by people with multiple sclerosis (MS) and a broader range of individuals with spinal cord injuries. Additionally,…
SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, according to clinical trial results. The Phase 1 clinical trial, which began dosing late last year, also showed…
Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data from a small Phase 1 clinical trial. Researchers used Octave’s MS Disease Activity (MSDA) scale — a clinically validated test for monitoring MS disease activity — and found the majority…
People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but levels of these antibodies are not associated with disease activity or clinical worsening among MS patients. That’s according to the study, “Evaluating the role of anti-EBV antibodies…